Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms

被引：73

作者：

Koulenti, Despoina ^{[1
,2
]}

Xu, Elena ^{[1
]}

Mok, Isaac Yin Sum ^{[1
]}

Song, Andrew ^{[1
]}

Karageorgopoulos, Drosos E. ^{[3
]}

Armaganidis, Apostolos ^{[2
]}

Lipman, Jeffrey ^{[1
,4
,5
]}

Tsiodras, Sotirios ^{[3
]}

机构：

[1] Univ Queensland, Fac Med, UQ Ctr Clin Res, Brisbane, Qld 4072, Australia

[2] Attikon Univ Hosp, Crit Care Dept 2, Athens 12462, Greece

[3] Attikon Univ Hosp, Dept Internal Med 4, Athens 12462, Greece

[4] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld 4029, Australia

[5] Univ Montpellier, Ctr Hosp Univ De Nimes CHU, Anesthesiol & Crit Care, F-30029 Nimes, France

来源：

MICROORGANISMS | 2019年 / 7卷 / 08期

关键词：

multidrug-resistance; gram-positive pathogens; novel antibiotics; ceftobiprole; ceftaroline; telavancin; oritavancin; dalbavancin; tedizolid; besifloxacin; delafloxacin; ozenoxacin; omadacycline; ACUTE BACTERIAL SKIN; IN-VITRO ACTIVITY; BROAD-SPECTRUM CEPHALOSPORIN; PENICILLIN-BINDING PROTEINS; SINGLE-DOSE ORITAVANCIN; STAPHYLOCOCCUS-AUREUS; STRUCTURE INFECTIONS; COMPLICATED SKIN; DOUBLE-BLIND; CEFTAROLINE FOSAMIL;

D O I：

10.3390/microorganisms7080270

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Increasing multidrug-resistance to Gram-positive pathogens, particularly to staphylococci, enterococci and streptococci, is a major problem, resulting in significant morbidity, mortality and healthcare costs. In recent years, only a small number of novel antibiotics effective against Gram-positive bacteria has been approved. This review will discuss the current evidence for novel branded antibiotics that are highly effective in the treatment of multidrug-resistant infections by Gram-positive pathogens, namely ceftobiprole, ceftaroline, telavancin, oritavancin, dalbavancin, tedizolid, besifloxacin, delafloxacin, ozenoxacin, and omadacycline. The mechanism of action, pharmacokinetics, microbiological spectrum, efficacy and safety profile will be concisely presented. As for any emerging antibiotic agent, resistance is likely to develop against these highly effective antibiotics. Only through appropriate dosing, utilization and careful resistance development monitoring will these novel antibiotics continue to treat Gram-positive pathogens in the future.

引用

页数：24

共 154 条

[1] Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia [J].

Abbott, I. J. ;

Jenney, A. W. J. ;

Jeremiah, C. J. ;

Mirceta, M. ;

Kandiah, J. P. ;

Holt, D. C. ;

Tong, S. Y. C. ;

Spelman, D. W. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (12) :7837-7841

[2]

Agency E. M, 2018, ORBACTIV

[3] In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against gram-positive and gram-negative organisms [J].

Almer, LS ;

Hoffrage, JB ;

Keller, EL ;

Flamm, RK ;

Shortridge, VD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (07) :2771-2777

[4]

[Anonymous], 2018, TEFLARO CEFT FOS INJ

[5] Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates [J].

Arhin, Francis F. ;

Draghi, Deborah C. ;

Pillar, Chris M. ;

Parr, Thomas R., Jr. ;

Moeck, Gregory ;

Sahm, Daniel F. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (11) :4762-4771

[6] Antibiotic Resistance Rates by Geographic Region Among Ocular Pathogens Collected During the ARMOR Surveillance Study [J].

Asbell, Penny A. ;

Pandit, Rahul T. ;

Sanfilippo, Christine M. .

OPHTHALMOLOGY AND THERAPY, 2018, 7 (02) :417-429

[7] A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia [J].

Awad, Samir S. ;

Rodriguez, Alejandro H. ;

Chuang, Yin-Ching ;

Marjanek, Zsuszanna ;

Pareigis, Alex J. ;

Reis, Gilmar ;

Scheeren, Thomas W. L. ;

Sanchez, Alejandro S. ;

Zhou, Xin ;

Saulay, Mikal ;

Engelhardt, Marc .

CLINICAL INFECTIOUS DISEASES, 2014, 59 (01) :51-61

[8]

Barber KE, 2017, J PHARMACOL PHARMACO, V8, P77, DOI 10.4103/jpp.JPP_2_17

[9] Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid [J].

Barber, Katie E. ;

Smith, Jordan R. ;

Raut, Animesh ;

Rybak, Michael J. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (01) :152-155

[10]

Basilea Pharmaceutical Basilea, 2019, BAS

← 1 2 3 4 5 6 7 8 9 10 →